Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulmatrix Inc (PULM)

Pulmatrix Inc (PULM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,785
  • Shares Outstanding, K 3,652
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,160 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta 1.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.54

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +9.17%
on 03/30/26
2.4900 -47.39%
on 03/20/26
-0.5800 (-30.69%)
since 03/02/26
3-Month
1.2000 +9.17%
on 03/30/26
3.4000 -61.47%
on 02/25/26
-0.9500 (-42.04%)
since 01/02/26
52-Week
1.2000 +9.17%
on 03/30/26
9.3700 -86.02%
on 05/29/25
-4.7500 (-78.38%)
since 04/02/25

Most Recent Stories

More News
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

FRAMINGHAM, Mass. and HOUSTON , March 26, 2026 /PRNewswire/ --  Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic...

PULM : 1.3100 (-0.76%)
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agreement...

PULM : 1.3100 (-0.76%)
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Plans to License or Monetize our Migraine and Inhalation Assets Continue

PULM : 1.3100 (-0.76%)
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission

PULM : 1.3100 (-0.76%)
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule...

PULM : 1.3100 (-0.76%)
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Proposed merger anticipated to close in 2025

PULM : 1.3100 (-0.76%)
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 1.3100 (-0.76%)
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious...

PULM : 1.3100 (-0.76%)
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...

PULM : 1.3100 (-0.76%)
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...

PULM : 1.3100 (-0.76%)

Business Summary

Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease...

See More

Key Turning Points

3rd Resistance Point 1.4832
2nd Resistance Point 1.4365
1st Resistance Point 1.3733
Last Price 1.3100
1st Support Level 1.2634
2nd Support Level 1.2167
3rd Support Level 1.1535

See More

52-Week High 9.3700
Fibonacci 61.8% 6.2491
Fibonacci 50% 5.2850
Fibonacci 38.2% 4.3209
Last Price 1.3100
52-Week Low 1.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.